EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting PD-1 and CD85j can restore intratumoral CD4 + GzmB + T-cell functions to combat MHC-II-expressing tumors

Boyu Wang, Xu Wang, Tianlai Wang, Kelin Meng, Taiyan Yu, Yu Xi, Shaojie Hu, Hui Xiong, Rirong Qu, Zhiwei Yuan, Xue Wang, Chenxi Zeng und 6 weitere

Journal for ImmunoTherapy of Cancer · 2025-04 · 13 (4) · e010890

DOI: 10.1136/jitc-2024-010890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.04.2025. Verfasst von Boyu Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, CD4-Positive T-Lymphocytes, Granzymes, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Finance of Hubei Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A subset of CD4 + T cells with cytotoxic activity has been identified, and these cells exert their effects by expressing perforin and granzymes. Despite the progress made in characterizing cytotoxic CD4 + T cells in various diseases, the status of cytotoxic CD4 + T cells in non-small cell lung cancer (NSCLC) and the underlying mechanisms involved in promoting intratumoral cytotoxic CD4 + T-cell activation remain unclear.

Methods

We used flow cytometry to examine the phenotypic and functional properties of CD4 + GzmB + T cells in the peripheral blood and tumor tissues of patients with NSCLC. Loss-of-function analyses and RNA sequencing were used to identify the underlying mechanisms involved in the effects of interleukin (IL)-15 on the restoration of CD4 + GzmB + T-cell function in vitro. A patient-derived lung cancer explant model and an animal model were used to verify the effects of immune checkpoint inhibitors on CD4 + GzmB + T-cell activation.

Results

In patients with NSCLC, impaired cytolytic function of tumor-infiltrated granzyme B (GzmB)-expressing CD4 + T cells was restored by IL-15 through activation of the AKT-FOXO1-T-bet axis. Moreover, IL-15 stimulation increased solute carrier family 7 member 5 (SLC7A5) expression in CD4 + GzmB + T cells in an Protein Kinase B (AKT)-dependent manner, and inhibition of SLC7A5 abrogated the effect of IL-15 on CD4 + GzmB + T cells. Additionally, we showed that the immune checkpoint molecules programmed cell death-1 (PD-1) and CD85j were mutually exclusively expressed in CD4 + GzmB + T cells and that dual targeting of PD-1 and CD85j enhanced the effector function of CD4 + GzmB + T cells by activating the AKT pathway. Notably, tumor cells expressing major histocompatibility complex (MHC)-II and IL-15 determine the effectiveness of CD4 + GzmB + T-cell-mediated antitumor immunity in response to immunotherapy.

Conclusions

Our study demonstrated that tumor-infiltrating CD4 + GzmB + T cells fail to eliminate tumors. Dual blockade of PD-1 and CD85j alongside IL-15 restores the effector function of CD4 + GzmB + T cells and drives CD4 + GzmB + T-cell transformation in the tumor microenvironment to combat MHC-II-expressing tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorCD4-Positive T-LymphocytesGranzymesLung NeoplasmsCarcinoma, Non-Small-Cell LungHistocompatibility Antigens Class IIImmune Checkpoint InhibitorsHumansAnimalsMiceInterleukin-15FemaleCell Line, Tumor

Stichwörter der Autor:innen

ImmunotherapyLung CancerTumor infiltrating lymphocyte - TIL

Substanzen

Programmed Cell Death 1 ReceptorGranzymesPDCD1 protein, humanHistocompatibility Antigens Class IIInterleukin-15GZMB protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, Hubei, China.
  • Department of Thoracic Surgery, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, Hubei, China lqli@tjh.tjmu.edu.cn fuxn2006@aliyun.com.

Förderung

  • Department of Finance of Hubei Province
  • National Natural Science Foundation of China

Zitieren

APA

Wang, B., Wang, X., Wang, T., Meng, K., Yu, T., Xi, Y., Hu, S., Xiong, H., Qu, R., Yuan, Z., Wang, X., Zeng, C., Zou, W., Tian, Y., Cai, Y., Fu, S., Fu, X., & Li, L. (2025). Targeting PD-1 and CD85j can restore intratumoral CD4 + GzmB + T-cell functions to combat MHC-II-expressing tumors. Journal for ImmunoTherapy of Cancer, 13(4), e010890. https://doi.org/10.1136/jitc-2024-010890

Vancouver

Wang B, Wang X, Wang T, Meng K, Yu T, Xi Y, et al. Targeting PD-1 and CD85j can restore intratumoral CD4 + GzmB + T-cell functions to combat MHC-II-expressing tumors. Journal for ImmunoTherapy of Cancer. 2025;13(4):e010890. doi:10.1136/jitc-2024-010890

BibTeX
@article{Wang2025,
  author = {Wang, Boyu and Wang, Xu and Wang, Tianlai and Meng, Kelin and Yu, Taiyan and Xi, Yu and Hu, Shaojie and Xiong, Hui and Qu, Rirong and Yuan, Zhiwei and Wang, Xue and Zeng, Chenxi and Zou, Wenbin and Tian, Yitao and Cai, Yixin and Fu, Shengling and Fu, Xiangning and Li, Lequn},
  title = {Targeting PD-1 and CD85j can restore intratumoral CD4 + GzmB + T-cell functions to combat MHC-II-expressing tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {e010890},
  doi = {10.1136/jitc-2024-010890}
}
Kostenlos starten →